Hyundai Bioscience and its special related parties maintained their total holdings of 20,614,284 shares, or 37.17% of Penetrium Bioscience, but increased the number of pledged shares by 90,000 from 9,503,700 to 9,593,700 shares.
This additional pledge was made by related party C&P, which expanded collateral from 63,700 to 153,700 shares for a 500 million KRW loan from Lotte Card, with a collateral maintenance ratio of 170%.
Hyundai Bioscience itself has already pledged 9 million shares as collateral for its convertible bond issued to Sangsangin Savings Bank and others, bringing total pledged shares to 17.30% of outstanding shares.
Hyundai Bioscience's total assets stand at approximately 130.7 billion KRW, liabilities 20 billion KRW, and equity 110.7 billion KRW. Related party C&P has assets of 87.6 billion KRW but liabilities of 81.1 billion KRW, indicating a very high debt ratio.
This additional pledge is unrelated to Penetrium's capital raising or new share issuance; however, in the event of default by the borrowers, the pledged shares could be dumped into the market, exerting downward pressure on the stock price.
[AI Summary]The additional share pledge by Hyundai Bioscience increases the financial burden on the largest shareholder without any capital change for Penetrium itself, raising the risk of share sales and management instability. While the absence of new issuance is positive, the potential overhang from pledged shares may cap stock price upside.